DDIF 2027 · The Why
01 · The gap
It fails in the gap between the people who made it and the people who were supposed to approve it. Drug discovery innovation stalls not for lack of science — but for lack of alignment across the decision chain.
02 · Three questions
What compounds.
Which molecules are worth the next decade of investment. Who makes that call and on what basis.
What translates.
How a compound moves from lab to GMP. The CMC decisions that determine whether a clinical candidate becomes a commercial medicine.
Who reaches the patient.
Regulatory strategy. Submission leadership. The people who determine whether the medicine is approved at all.
03 · The room
Scientists. CMC leads. Regulatory strategists. Decision-makers across the full chain. The Savoy, London. 12–13 May 2027. Closed-door. By invitation.
For the molecule. For the medicine. For the patient.